Schizophrenia Research
Volume 44, Issue 3 , Pages 177-181 , 1 September 2000

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response1

  • Shih-Jen Tsai

      Affiliations

    • Department of Psychiatry, Veterans General Hospital Taipei, Taipei, Taiwan
    • Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Chen-Jee Hong

      Affiliations

    • Department of Psychiatry, Veterans General Hospital Taipei, Taipei, Taiwan
    • Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886-2-2875-7027 (ext. 304); fax: +886-2-2872-5643
    • ,
  • Younger W.-Y. Yu

      Affiliations

    • Kai-Suan Psychiatric Hospital, Kaohsiung, Taiwan
    • ,
  • Ching-Hua Lin

      Affiliations

    • Kai-Suan Psychiatric Hospital, Kaohsiung, Taiwan
    • ,
  • Hsiu-Li Song

      Affiliations

    • Department of Psychiatry, Veterans General Hospital Taipei, Taipei, Taiwan
    • ,
  • Hao-Che Lai

      Affiliations

    • Department of Psychiatry, Veterans General Hospital Taipei, Taipei, Taiwan
    • ,
  • Kuan-Hung Yang

      Affiliations

    • Kai-Suan Psychiatric Hospital, Kaohsiung, Taiwan

Received 3 September 1999 ,Accepted 3 September 1999.

References 

  1. Austin MC, Bradley CC, Mann JJ, Blakely RD. Expression of serotonin transporter messenger RNA in the human brain. J. Neurochem. 1994;62:2362–2367
  2. Bonnet-Brilhault F, Laurent C, Thibaut F, Campion D, Chavand O, Samolyk D, et al. Serotonin transporter gene polymorphism and schizophrenia: an association study. Biol. Psychiatry. 1997;42:634–636
  3. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am. J. Psychiatry. 1996;153:1625–1627
  4. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J. Clin. Psychopharmacol. 1997;17:68–69
  5. Curtis VA, Wright P, Reveley A, Kerwin R, Lucey JV. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br. J. Psychiatry. 1995;166:642–646
  6. Dean B, Opeskin K, Pavey G, Naylor L, Hill C, Keks N, et al. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J. Neurochem. 1995;64:1197–1202
  7. Dean B, Hayes W, Opeskin K, Naylor L, Pavey G, Hill C, et al. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 1996;73:169–175
  8. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 1996;66:2621–2624
  9. Hernandez I, Sokolov BP. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics. Mol. Psychiatry. 1997;2:57–64
  10. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL. Serotonin function and treatment response to clozapine in schizophrenic patients. Am. J. Psychiatry. 1993;150:1337–1342
  11. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796
  12. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psychiatry. 1993;50:810–818
  13. Lin C-H, Tsai S-J, Yu YW-Y, Song H-L, Tu P-C, Sim C-B, et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport. 1999;10:57–60
  14. Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol. Psychiatry. 1998;3:328–332
  15. Meltzer HY. An overview of the mechanism of action of clozapine. J. Clin. Psychiatry. 1994;55(Suppl B):47–52
  16. Mendes de Oliveira JR, Otto PA, Vallada H, Lauriano V, Elkis H, Lafer B, et al. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. Am. J. Med. Genet. 1998;81:225–227
  17. Overall JF, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962;10:799–812
  18. Serretti A, Catalano M, Smeraldi E. Serotonin transporter gene is not associated with symptomatology of schizophrenia. Schizophr. Res. 1999;35:33–39
  19. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychopharmacol. 1998;18:208–211
  20. Stober G, Jatzke S, Heils A, Jungkunz G, Fuchs E, Knapp M, et al. Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene. Eur. Arch. Psychiatry Clin. Neurosci. 1998;248:82–86
  21. Yu YW-Y, Tsai S-J, Lin C-H, Hsu C-P, Yang K-H, Hong C-J. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport. 1999;10:1231–1233

PII: S0920-9964(99)00170-X

Schizophrenia Research
Volume 44, Issue 3 , Pages 177-181 , 1 September 2000

Article Tools